Mark Egly Foundation
  • Why We Exist
    Our Mission
    Our PromiseOur ImpactOur AgendaMark's StoryMark's PatentCurrent Partnerships
    Standard of Care
    What is the SOCChanging the SOCOur Research StrategyKey InitiativesNews
    Alpha1 Antitrypsin
    State of the FieldOur Research StrategyKey Research InitiativesResearch News
  • Understanding Alpha1
    About Alpha1
    What is Alpha1What is Alpha1 Antitrypsin DeficiencySymptomsMedication & TreatmentsRelated ConditionsAge Relevance to Diagnosis
    Alpha1 Journey
    Newly Diagnose ResourcesAlpha1 360Building a Support TeamWork & Financial ConcernsRelationshipsMental & Physical Health
    Education & Inspiration
    Alpha1 and You EventsAsk the MDWebinarsPodcastsBooks & ResourcesAlpha1 Friend Network
  • For Researchers
    Apply for Grants
    What We FundFunding OpportunitiesWorking with UsFunded Studies
  • Take Action
    Donate
    Donate NowMonthly Giving ProgramWays to GiveIn TributeEmployee GivingPlanned Giving
    Advocate
    Contact Your PolicymakersOur Public Policy PrioritiesAdvocacy ResourcesPolicy Updates

Age Relevance to Diagnosis

The age that someone is diagnosed or becomes knowledgeable that they have at least one allele of potential danger is imperative!

Why?

Degradation of any body region may be going on in earlier ages. Previously, an Alpha1 Antitrypsin Deficient person had to wait for the manifestation of a disease to realize they may have been sick for decades and their body had already been facing a gradual decline that has the potential to be 100% avoided with proper management of circulating Alpha1 Antitrypsin levels in their bodies!

It is Mark and the Foundation's dream that Alpha1 Antitrypsin becomes the equivalent of the safest and healthiest "vaccine type" treatment many individuals could receive throughout their entire lifetime.